Sellas Life Sciences Group Inc Stock Price, News & Analysis

SELLAS Life Sciences Group (SLS) reported significant clinical updates on Galinpepimut-S (GPS), showcasing its potential in treating malignant pleural mesothelioma and WT1+ advanced ovarian cancer. The company highlighted results from a study showing an overall survival (OS) of 48.5 months for AML patients treated with GPS. Financially, SLS recorded licensing revenue of $1.9 million for Q2 2021, with a cash position of $29.9 million as of June 30, 2021. A virtual investor symposium is scheduled for August 17, 2021, to discuss further insights on GPS and its promising clinical data.

SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, will host a virtual investor symposium on August 17, 2021, focusing on its lead asset, galinpepimut-S (GPS). The event will detail GPS's clinical program and recent data regarding acute myeloid leukemia (AML) treatment. Notably, Dr. Yair Levy, a leading cancer researcher, will join the management team. GPS targets the WT1 protein in various tumors and has potential for treating hematologic malignancies and solid tumors.

SELLAS Life Sciences Group (NASDAQ: SLS) reported encouraging results from its Phase 1/2 clinical trial of its lead immunotherapy, galinpepimut-S (GPS), combined with pembrolizumab for advanced ovarian cancer. Notably, 100% of patients are alive, and 45.5% continue with the treatment. CD8+ T-cell responses increased by an average of +242%, indicating robust immune activation. The disease control rate was 63.6%, with a median progression-free survival of 11.8 weeks in a challenging patient cohort. These findings suggest potential for GPS as a viable therapy in difficult-to-treat cases.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced promising results from a Phase 1 trial combining its lead candidate, galinpepimut-S (GPS), with nivolumab for treating malignant pleural mesothelioma (MPM). Patients showed a median overall survival of 35.4 weeks, compared to approximately 28 weeks with standard care. The combination therapy appears to provide significant clinical benefits, especially for patients who have failed traditional treatments. SELLAS plans to provide further clinical data by the end of Q4 2021.

SELLAS Life Sciences Group (Nasdaq: SLS) announced its inclusion in the Russell Microcap Index, effective June 28, 2021. This inclusion is a significant milestone expected to enhance the company's visibility within the investment community. SELLAS, known for developing cancer immunotherapies, notably its lead candidate GPS, aims to provide treatment options for various cancer types. The Russell Microcap Index inclusion lasts for a year and is determined by market capitalization and style attributes, impacting approximately $10.6 trillion in assets.

SELLAS Life Sciences Group announced the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering galinpepimut-S (GPS) in combination with checkpoint inhibitors for treating WT1-expressing cancers. This patent extends to at least 2036 and facilitates further clinical studies for patients with advanced ovarian cancer and malignant pleural mesothelioma. CEO Angelos Stergiou emphasized the importance of this milestone for advancing their clinical pipeline and intends to release more data later this quarter.

SELLAS Life Sciences Group (SLS) announced a milestone payment of $1.0 million from 3D Medicines under an exclusive license for Galinpepimut-S (GPS) in Greater China. The company recognized $5.7 million in licensing revenue for Q1 2021 and received approval for the Phase 3 REGAL study in Greece, with patient enrollment planned in France and Germany by Q2. R&D expenses rose to $4.3 million due to increased clinical preparations, while general and administrative expenses reached $3.6 million. The net loss narrowed to $2.4 million, with cash reserves at approximately $28 million.

SELLAS Life Sciences Group (Nasdaq: SLS) will hold a Shareholder Update Call on June 3, 2021, at 8:30 a.m. ET, hosted by President & CEO Angelos Stergiou. The call will provide a corporate update on the company’s progress and future plans in developing cancer immunotherapies.

Participants can join via toll-free numbers or online, with a replay available until June 17, 2021. The company's lead product candidate, galinpepimut-S (GPS), targets the WT1 protein for various cancers, while nelipepimut-S (NPS) aims to treat early-stage HER2+ breast cancer.

SELLAS Life Sciences Group (SLS) has signed an exclusive license agreement with 3D Medicines for the development and commercialization of Galinpepimut-S (GPS) in China, receiving a $7.5 million upfront fee and potential total payments of $202 million. As of December 31, 2020, SELLAS reported cash and equivalents of $35.3 million, a significant increase from prior periods. The ongoing Phase 3 REGAL study in Acute Myeloid Leukemia has expanded to approximately 135 clinical sites. Additionally, preliminary clinical data show promising results for GPS in combination with therapies for ovarian cancer and mesothelioma.